VIDEO: ADAURA trial ‘paradigm-shifting’ for lung cancer precision medicine

In this video, Vivek Subbiah, MD, associate professor at The University of Texas MD Anderson Cancer Center, shares his perspective on the results from the ADAURA trial, a “potentially paradigm-shifting phase 3 study.”

“This is interesting because in April 2020, it was announced that the trial would be unblinded early following a recommendation from an independent monitoring company that determined there was an overwhelming efficacy with EGFR TKI,” Subbiah explained.

The FDA first approved osimertinib for the treatment of patients with metastatic EGFR-mutated non-small cell lung cancer (NSCLC) in 2015, and the ADAURA trial data may support adjuvanted therapy with osimertinib.

“Lessons from the study can be useful for us in the world of precision medicine,” Subbiah said.

References:

Herbst RS, et al. Abstract LBA5. Presented at: ASCO20 Virtual Scientific Program; May 29-31, 2020.

Published by:

Sources/Disclosures

Collapse

Disclosures: Subbiah reports serving in a consulting or advisory role for Helsinn Therapeutics, Loxo, MedImmune, QED Pharma and R-Pharma-US and receiving research funding to his institution from Abbvie, Agensys, Alfasigma, Amgen, Bayer, Berg Pharma, Blueprint Medicines, Boston Biomedical, D3 Onology Solutions, Exelixis, Fujifilm, Genentech/Roche, GlaxoSmithKline, Idera, Incyte, Inhibrx, LOXO, Multivir, NanoCarrier, Northwest Biotherapeutics, Novartis, Pfizer, PharmaMar, Takeda, Turningpoint Therapeutics and Vegenics. He also reports receiving travel, accommodations and expenses from Bayer, Helsinn Therapeutics, Novartis and PharmaMar, and reports a relationship with Medscape.

Take Homes in Lung Cancer

Read more

VIDEO: ADAURA trial ‘paradigm-shifting’ for lung cancer precision medicine

References:

Related Content